Noticias y notas de prensa

PPTA considers that the SARS-CoV-2 outbreak is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies. The assessment is shared by notable international and national public health bodies, including the WHO, the ECDC, and others.

An article published March 25 by Stefanie Dodt and Samuel Gilbert in The Guardian continues the authors’ intentional maligning of plasma donors along the U.S.-Mexico border and perpetuates a divisive misrepresentation of the reality of border life between the United States and Mexico.

New report analyses clinical, economic, and societal perspectives for patient access.

At this time of global concern regarding spread of the novel coronavirus, PPTA wants to thank the millions of committed plasma donors who make lifesaving medicines for rare disease patients a reality and to remind them that donor safety continues to be a top priority for PPTA and its member companies.